Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002986 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00002986 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 36 participants.
The verdict
NCT00002986, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent primary malignant glioma.
Interventions
- DRUG carmustine
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1997-02 |
| Est. Completion | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002986
The ClinicalTrials.gov registry entry for NCT00002986 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carmustine is the first listed.
NCT00002986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002986 about?
NCT00002986 is a clinical study titled "Chemotherapy in Treating Patients With Recurrent Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent primary malignant glioma.
What is the current status of trial NCT00002986?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 1997-02. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00002986?
The interventions under investigation include: carmustine (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002986?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.